1. Home
  2. NAD vs WGS Comparison

NAD vs WGS Comparison

Compare NAD & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Quality Municipal Income Fund

NAD

Nuveen Quality Municipal Income Fund

N/A

Current Price

$12.06

Market Cap

2.9B

Sector

Finance

ML Signal

N/A

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

N/A

Current Price

$90.49

Market Cap

2.3B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
NAD
WGS
Founded
1999
2017
Country
United States
United States
Employees
N/A
1300
Industry
Investment Managers
Retail: Computer Software & Peripheral Equipment
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NAD
WGS
Price
$12.06
$90.49
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$140.71
AVG Volume (30 Days)
644.8K
738.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.35%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$29.98
Revenue Next Year
N/A
$24.85
P/E Ratio
N/A
$1,251.58
Revenue Growth
N/A
N/A
52 Week Low
$10.40
$55.17
52 Week High
$12.31
$170.87

Technical Indicators

Market Signals
Indicator
NAD
WGS
Relative Strength Index (RSI) 41.45 50.84
Support Level $12.00 $78.80
Resistance Level $12.14 $95.94
Average True Range (ATR) 0.07 5.50
MACD -0.02 1.89
Stochastic Oscillator 31.08 87.78

Price Performance

Historical Comparison
NAD
WGS

About NAD Nuveen Quality Municipal Income Fund

Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: